The cuts and reduction of research activities are designed to help ImmunoGen ration $240 million in cash long enough to finish its phase 3 clinical trial of mirvetuximab and prioritize three other earlier stage drug candidates, the company said.
ImmunoGen plans to suspend all other research activities.
Most of the layoffs will occur by mid-July. The cuts are expected to cut ImmunoGen’s quarterly expenses in half.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
